Prostatic Neoplasms Clinical Trial
Official title:
Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations - Open Label Randomized Pilot Study
Radical prostatectomy has become the gold standard treatment for prostate cancer.
Regarding of morbidity of access on open retropubic radical prostatectomy a lot of centers
around the world start to develop laparoscopic and robotic approach over the past years. The
problems regarding this techniques is that the pure laparoscopic prostatectomy shows a steep
learning curve with a high initial complication rate, and the use of robotic assistance
surgery despite of lower learning curve is associated with higher surgical supply and
operative room costs. These costs may have a significant impact on overall cost of prostate
cancer care especially in Brazil.
In Brazil, the open route for radical prostatectomy is still the most frequent approach. One
of the disadvantages of open prostatectomy from the other surgeries is the longest hospital
stay. However, the question of what length of stay after this operation is optimal and
necessary is unresolved. In this trial the investigators have compared a randomized group of
patients that had discharged on postoperative day 2, 1 and same day surgery. The
investigators had intent to evaluate the feasibility of ambulatory open radical
prostatectomy (patient discharge in the same day of surgery - average 12 hours of
hospitalization) maintaining patient satisfaction and safety.
Radical prostatectomy initially described by Walsh (1982) has become the gold standard
treatment for prostate cancer and has evolved enormously over the last 25 years.
Improvements include the use of smaller incisions, reduced blood loss, shorter hospital
stays, and surgical refinement. Several large series with long-term follow-up have confirmed
that this approach results in excellent cancer control and functional results in terms of
preservation of erectile potency and urinary continence.
Regarding of morbidity of access on open retropubic radical prostatectomy a lot of centers
around the world start to develop laparoscopic and robotic approach over the past years. The
problems regarding this techniques is that the pure laparoscopic prostatectomy shows a steep
learning curve with a high initial complication rate, and the use of robotic assistance
surgery despite of lower learning curve is associated with higher surgical supply and
operative room costs. These costs may have a significant impact on overall cost of prostate
cancer care especially in Brazil where nowadays only have 3 centers with 5 robots.
In Brazil, the open route for radical prostatectomy is still the most frequent approach,
mainly out of large cities. One of the disadvantages of open prostatectomy from minimally
invasive surgeries is the longest hospital stay. However, the question of what length of
stay after this operation is optimal and necessary is unresolved. In this trial the
investigators have compared a randomized group of patients that had discharged on
postoperative day 2, 1 and same day surgery. The investigators had intent to evaluate the
feasibility of ambulatory open radical prostatectomy (patient discharge in the same day of
surgery - average 12 hours of hospitalization) while maintaining patient satisfaction and
safety.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
| Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
| Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
| Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
| Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
| Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
| Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
| Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |